Bristol-Myers Squibb Company (BMY) on Decifer

Decifer ranks BMY number 96 of 270 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 15% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is not growing right now and profits grew 178% over the past year.
• It keeps a high share of every sale as profit, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Strong returns of 15% with profits up 178% provide quality, but flat revenue, momentum of 13 in a lagging sector, and no funded role limit upside.

The current read

The evidence on BMY lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full BMY research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.